Blog
RSS FeedPosted by Michael Wonder on 31 Aug 2025
FDA approval of Leqembi subcutaneous formulation charts path to combination therapies for Alzheimer's disease
29 August 2025 - Subcutaneous delivery increases accessibility and introduces potential for at home administration, following model of diabetes and ...
Posted by Michael Wonder on 22 Mar 2022
Valeo Pharma secures additional public reimbursement for Redesca, Enerzair Breezhaler and Atectura Breezhaler
22 March 2022 - Canadian provincial public reimbursement now complete for Redesca with the addition of British Columbia. ...
Posted by Michael Wonder on 22 Mar 2022
Doctors break rules for prescribing safe-sex drug as PHARMAC considers change
22 March 2022 - Doctors flagrantly broke rules for prescribing a safe-sex drug during 2021 COVID-19 lockdowns. ...
Posted by Michael Wonder on 22 Mar 2022
Hope for quadriplegics as ‘miracle treatment’ gets green light from regulator
21 March 2022 - In a major step forward for treating victims of paralysis, Australian regenerative medicine company Orthocell has ...
Posted by Michael Wonder on 22 Mar 2022
Ascentage Pharma's MDM2-p53 inhibitor alrizomadlin (APG-115) granted rare paediatric disease designation by the US FDA for the treatment of neuroblastoma
21 March 2022 - Ascentage Pharma today announced that its novel MDM2-p53 inhibitor, alrizomadlin (APG-115), was granted a rare paediatric disease ...
Posted by Michael Wonder on 22 Mar 2022
KYE Pharmaceuticals files Accrufer new drug submission in Canada for the treatment of iron deficiency
21 March 2022 - Shield Therapeutics announces that KYE Pharmaceuticals has submitted a new drug submission to Health Canada for ...
Posted by Michael Wonder on 22 Mar 2022
Travere Therapeutics submits new drug application for sparsentan for the treatment of IgA nephropathy
21 March 2022 - Travere Therapeutics today announced that it has submitted a new drug application to the U.S. FDA ...
Posted by Michael Wonder on 22 Mar 2022
Prescription medicines: applications under evaluation (March 2022)
22 March 2022 - The TGA has updated its list of applications for new medicines or new uses for existing ...
Posted by Michael Wonder on 21 Mar 2022
FDA approves pembrolizumab for advanced endometrial carcinoma
21 March 2022 - Today, the FDA approved pembrolizumab (Keytruda, Merck), as a single agent, for patients with advanced endometrial ...
Posted by Michael Wonder on 21 Mar 2022
Government to introduce oral COVID-19 medicine Lagevrio for 100,000 patients this week: interior minister
21 March 2022 - The Government will introduce the oral antiviral medicine Lagevrio for 100,000 patients this week while seeking ...
Posted by Michael Wonder on 21 Mar 2022
China’s NMPA grants greater access to rheumatology biosimilars
22 March 2022 - Since the start of 2022, China’s National Medicinal Products Agency has made strides to increase greater ...
Posted by Michael Wonder on 21 Mar 2022
New Australian agency to accelerate genomic research and drive innovation in health care
21 March 2022 - Genomics advances will help develop revolutionary treatments for some of our biggest health challenges, including diagnosing ...
Posted by Michael Wonder on 21 Mar 2022
CADTH releases its annual list of health technology trends to watch
18 March 2022 - New horizon scan report offers insights on health technology trends that have the potential to harness ...
Posted by Michael Wonder on 21 Mar 2022
Provention Bio announces FDA acceptance of the biologics license application resubmission for teplizumab for the delay of clinical type 1 diabetes in at-risk individuals
21 March 2022 - FDA Sets Goal Date of August 17, 2022. ...
Posted by Michael Wonder on 21 Mar 2022
NICE recommends elosulfase alfa for routine NHS use for patients with rare life-limiting metabolic disorder
21 March 2022 - NICE has today published final draft guidance recommending elosulfase alfa (Vimizim; BioMarin) for routine use in ...
Posted by Michael Wonder on 21 Mar 2022
Takeda’s Exkivity (mobocertinib) granted conditional marketing authorisation in Great Britain
18 March 2022 - The considerable unmet need in this patient population means oral mobocertinib has been granted an Innovation Passport ...